smart insulin (GRI) / Novo Nordisk - LARVOL DELTA

From economics to health outcomes: Delving into the significance of reduced insulin prices. (PubMed, S Afr Med J) - "The introduction of smart insulin pens adds a technological dimension, but concerns persist about equitable access. Urging policy-makers to re-evaluate guidelines and decolonise the EML, the article emphasises enhancing patient quality of life and reducing the disease burden."

HEOR • Journal • Metabolic Disorders

Improvement in time in range after smart insulin pen initiation in Austria (EASD 2024) - "Real-world data from Austria shows a clear glycaemic improvement after smart insulin pen initiation. Analysing country-specific experiences is important to understand the potential impact of smart insulin pen use and how PLWD and physicians can most benefit from this technology."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Multinational analysis of factors associated with missed bolus insulin injections using smart pen data (EASD 2024) - "Bolus insulin adherence increased with age and smart pen engagement and decreased on weekends. Smart insulin pen data can provide novel insights into individuals’ real-world injection behaviours."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effectiveness and safety of telemonitoring compared with usual care in people with type 2 diabetes treated with insulin: preliminary results from a national multicentre randomised controlled trial (EASD 2024) - P=N/A | "The telemonitoring group was provided with a continuous glucose monitor (CGM), a smart insulin pen, and an activity tracker... The preliminary results indicate a strong effect of telemonitoring over usual care for improving glycemic control in people with insulin-treated T2D."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Multinational Analysis of Factors Associated with Missed Bolus Insulin Injections Using Smart Pen Data (ADA 2024) - "Bolus insulin adherence increased with age and smart pen engagement and decreased on weekends. Smart insulin pen data can provide novel insights into individuals' real-world injection behaviors."

Diabetes • Metabolic Disorders

Multinational Analysis of Factors Associated with Missed Bolus Insulin Injections Using Smart Pen Data (ADA 2024) - "Bolus insulin adherence increased with age and smart pen engagement and decreased on weekends. Smart insulin pen data can provide novel insights into individuals' real-world injection behaviors."

Diabetes • Metabolic Disorders

Improvement in time in range after smart pen initiation in routine clinical practice (EASD 2023) - "Among PLWD initiating a smart insulin pen for their bolus insulin, there was a significant increase in TIR after 3 months, with the greatest improvements seen in those who had the lowest TIR in the baseline period. In addition, there was a significant decrease in TBR after 3 months. Similar changes in TIR and TBR were seen at 6 months but were not statistically significant owing to fewer PLWD having data at this timepoint."

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Characteristics of priming behaviour among individuals with diabetes using NovoPen 6 in a real-world setting (EASD 2023) - "Fewer than half of administered doses were preceded by a priming dose. Participants almost always or almost never primed their insulin pens; factors associated with priming behaviour included younger age, dosing frequently or taking smaller doses. These findings highlight the new opportunity that smart insulin pens present to observe real world insulin therapy management by people with diabetes."

Clinical • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Association between treatment adherence and continuous glucose monitoring outcomes in people with diabetes using smart insulin pens in a real-world setting (EASD 2023) - "Materials and Data were collected from adults (≥18 years) administering basal insulin (degludec) and bolus insulin (aspart or faster aspart) using smart insulin pens with continuous glucose monitoring (CGM); data were aggregated in 14-day periods. These real-world data confirm associations between missed basal and bolus insulin doses and impaired TIR, highlighting a need for digital tools such as smart insulin pens to help individuals manage their diabetes."

Adherence • Clinical • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Smart digital solutions: Integrating therapy and care for people with diabetes (EASD 2022) - "Sponsored by Novo Nordisk A/S (Smart insulin pens: advancing digital care for diabetes)"

Diabetes • Metabolic Disorders

"⁦@Roche's⁩ ⁦@mysugr⁩ #app + ⁦⁦@novonordisk⁩'s #smartinsulin pens via ⁦@MobiHealthNews⁩ While hardly Novo Nordisk's first integration, always encouraging to see #OpenInnovation in action in #digitalhealth. #digital #diabetes https://t.co/B1O800buCr" (@DevmalyaS)

Diabetes • Metabolic Disorders

OBSERVATION OF GLYCAEMIC MANAGEMENT IN PROFESSSIONAL CYCLISTS WITH TYPE 1 DIABETES OVER A 7-DAY WORLD TOUR STAGE RACE (ATTD 2020) - "Insulin dosage and timing was recorded using NovoPen® Echo Plus (Novo Nordisk, Bagsværd, Denmark) smart insulin pens...In-ride carbohydrate intakes of this group of athletes (76±23 g∙h-1) coincide with the contemporary nutrition guidelines for endurance athletes t41=1.69, p=0.09. Conclusions Despite the many glycaemic challenges, the CGM data show that professional cyclists with T1D spent a high percentage of their time in target glycaemic range, with little time in hypoglycaemia over a World Tour stage race."